Procyon Advisors’s SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-2,831
| Closed | -$207K | – | 524 |
|
|
2023
Q3 | $207K | Sell |
2,831
-500
| -15% | -$36.5K | 0.02% | 453 |
|
|
2023
Q2 | $277K | Sell |
3,331
-114
| -3% | -$9.49K | 0.03% | 368 |
|
|
2023
Q1 | $263K | Buy |
3,445
+519
| +18% | +$39.6K | 0.04% | 328 |
|
|
2022
Q4 | $243K | Sell |
2,926
-1,198
| -29% | -$99.4K | 0.04% | 323 |
|
|
2022
Q3 | $327K | Buy |
+4,124
| New | +$327K | 0.08% | 230 |
|
|
2021
Q4 | – | Sell |
-1,667
| Closed | -$210K | – | 347 |
|
|
2021
Q3 | $210K | Buy |
1,667
+1
| +0.1% | +$126 | 0.05% | 296 |
|
|
2021
Q2 | $226K | Buy |
1,666
+2
| +0.1% | +$271 | 0.06% | 268 |
|
|
2021
Q1 | $226K | Sell |
1,664
-135
| -8% | -$18.3K | 0.1% | 216 |
|
|
2020
Q4 | $253K | Buy |
+1,799
| New | +$253K | 0.12% | 186 |
|
|
2020
Q3 | – | Sell |
-791
| Closed | -$89K | – | 1071 |
|
|
2020
Q2 | $89K | Sell |
791
-94
| -11% | -$10.6K | 0.05% | 303 |
|
|
2020
Q1 | $69K | Buy |
885
+110
| +14% | +$8.58K | 0.05% | 288 |
|
|
2019
Q4 | $74K | Buy |
+775
| New | +$74K | 0.05% | 297 |
|